Image

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries. In New Caledonia, dengue epidemics are recurrent and may be associated with the co-circulation of other arboviruses such as Zika or chikungunya.

The virological determinants which condition the occurrence of these epidemics may be linked to an increased vectorial competence of the vector mosquito Aedes aegypti for a particular viral isolate. In fact, the Aedes aegypti mosquito is infected by making a blood meal on a person infected with an arbovirus. The virus infects its digestive tract, then spreads throughout the mosquito's body until it reaches its salivary glands. The virus is then present in the saliva and will be injected into the human host during a new blood meal. Some viral variants are best transmitted by Aedes aegypti. In general, the study of this vectorial competence is carried out by experiments in the laboratory during which an artificial blood meal composed of mammalian blood (human, rabbit, etc.) is mixed with a viral stock. Carrying out deported blood meals during which blood collected from patients infected with an arbovirus is used to gorge mosquitoes makes it possible to place oneself in experimental conditions as close as possible to the natural cycle of transmission of arboviruses.

In the human host, cells of the myeloid lineage present in the peripheral blood constitute preferred targets of replication for arboviruses. At the same time, the peripheral blood cells of patients are activated in response to infection and secrete many soluble factors released into the blood of patients. The study of blood samples from patients infected with arboviruses is therefore of prime importance for understanding both the replicative mechanisms of arboviruses but also the immune response they induce.

Description

Collection of blood samples from adult patients with clinical signs suggestive of arbovirus

This study is a interventional study that present minimal risks and constraints.

This study will improve :

  • the reliability of the results of vector competence experiments
  • the understanding of the mechanisms of infection and replication of arboviruses
  • the knowledge of the immune mechanisms involved in the response to infection by an arbovirus

Eligibility

Inclusion Criteria:

  • Major patient
  • Patient with clinical signs suggestive of an arbovirus infection:
        Fever And at least 2 clinical signs suggestive of arbovirus among which myalgia,
        retro-orbital pain, drop in platelets (if data available), digestive symptoms, etc.
          -  Appearance of clinical signs suggestive of an arbovirus infection in the 7 days
             preceding the blood sample.
          -  Patient informed of the performance of the research, the collection of data and
             biological samples
          -  Patient who has given their consent to participate in the research by authorizing the
             collection of data, the collection of an additional blood sample and the use of this
             sample
        Exclusion Criteria:
          -  Patient suffering from another identified virosis, an inflammatory disease or taking
             anti-inflammatory drugs
          -  Pregnant patient
          -  Patient returning from a trip within 15 days before the onset of the signs,
          -  Patient for whom the blood sample is incomplete or could not be performed
          -  Patient's condition, which, in the doctor's opinion, is incompatible with the
             additional sample required by the study
          -  Patient not having consented to participate in the research

Study details
    Arbovirus Infections
    Zika
    Dengue
    Chikungunya

NCT04619823

Institut Pasteur

28 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.